Boston Scientific (BSX) EBITDA Margin: History & Chart

Boston Scientific Corporation(BSX)

Medical - Devices · Marlborough, MA

$43.93-1.12 (-2.49%)

Delayed quote: Sep 15, 2026, 10:30 AM EDT

About Boston Scientific Corporation

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Marlborough, MA

59,000 employees

www.bostonscientific.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Michael F. Mahoney

View full financials

BSX EBITDA Margin Metrics

EBITDA MARGIN

26.60%

EBITDA MARGIN AVG TTM

26.66%

EBITDA MARGIN AVG 3Y

24.99%

EBITDA MARGIN AVG 5Y

24.31%

EBITDA MARGIN AVG 10Y

24.75%

EBITDA MARGIN AVG 15Y

21.30%

EBITDA MARGIN AVG 20Y

20.75%

CURRENT VS TTM AVG

-0.23%

CURRENT VS 3Y AVG

+6.42%

CURRENT VS 5Y AVG

+9.42%

CURRENT VS 10Y AVG

+7.48%

CURRENT VS 15Y AVG

+24.86%

CURRENT VS 20Y AVG

+28.19%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Boston Scientific Corporation (BSX)	$65.30B	26.60%	26.66%	24.99%	24.31%
Cencora, Inc. (COR)vs ›	$62.66B	1.46%	1.44%	1.41%	1.40%
Moderna, Inc. (MRNA)vs ›	$56.92B	-147.07%	-132.24%	-66.39%	-46.73%
Cardinal Health, Inc. (CAH)vs ›	$54.68B	1.40%	1.39%	1.08%	0.86%
Cigna Corporation (CI)vs ›	$76.15B	4.28%	4.40%	4.95%	5.27%
Regeneron Pharmaceuticals, Inc. (REGN)vs ›	$80.01B	28.74%	30.12%	35.91%	41.00%
Becton, Dickinson and Company (BDX)vs ›	$50.19B	23.08%	23.14%	23.23%	22.53%
Edwards Lifesciences Corporation (EW)vs ›	$49.18B	29.55%	28.88%	30.96%	31.73%
Humana Inc. (HUM)vs ›	$47.88B	1.76%	1.98%	3.17%	4.08%
Teva Pharmaceutical Industries Limited (TEVA)vs ›	$44.90B	18.31%	11.44%	6.73%	5.67%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Boston Scientific Corporation (BSX)

$65.30B

26.60%

26.66%

24.99%

24.31%

Cencora, Inc. (COR)vs ›

$62.66B

1.46%

1.44%

1.41%

1.40%

Moderna, Inc. (MRNA)vs ›

$56.92B

-147.07%

-132.24%

-66.39%

-46.73%

Cardinal Health, Inc. (CAH)vs ›

$54.68B

1.40%

1.39%

1.08%

0.86%

Cigna Corporation (CI)vs ›

$76.15B

4.28%

4.40%

4.95%

5.27%

Regeneron Pharmaceuticals, Inc. (REGN)vs ›

$80.01B

28.74%

30.12%

35.91%

41.00%

Becton, Dickinson and Company (BDX)vs ›

$50.19B

23.08%

23.14%

23.23%

22.53%

Edwards Lifesciences Corporation (EW)vs ›

$49.18B

29.55%

28.88%

30.96%

31.73%

Humana Inc. (HUM)vs ›

$47.88B

1.76%

1.98%

3.17%

4.08%

Teva Pharmaceutical Industries Limited (TEVA)vs ›

$44.90B

18.31%

11.44%

6.73%

5.67%

EBITDA Margin FAQ

What is the EBITDA margin for Boston Scientific Corporation (BSX)?

The EBITDA margin for BSX stock is 26.60%.

Is Boston Scientific Corporation's EBITDA margin high or low?

The EBITDA margin of 26.60% is in line with its 5-year average of 24.31%, around the middle of its 5-year range (20.54%–29.72%).

What is the TTM average EBITDA margin for Boston Scientific Corporation (BSX)?

The TTM average EBITDA margin for BSX stock is 26.66%.

What is the 3Y average EBITDA margin for Boston Scientific Corporation (BSX)?

The 3Y average EBITDA margin for BSX stock is 24.99%.

What is the 5Y average EBITDA margin for Boston Scientific Corporation (BSX)?

The 5Y average EBITDA margin for BSX stock is 24.31%.

What is the 10Y average EBITDA margin for Boston Scientific Corporation (BSX)?

The 10Y average EBITDA margin for BSX stock is 24.75%.

What is the 15Y average EBITDA margin for Boston Scientific Corporation (BSX)?

The 15Y average EBITDA margin for BSX stock is 21.30%.

What is the 20Y average EBITDA margin for Boston Scientific Corporation (BSX)?

The 20Y average EBITDA margin for BSX stock is 20.75%.

DATE	EBITDA MARGIN
2026-06-30	25.93%
2026-03-31	27.35%
2025-12-31	29.72%
2025-09-30	27.48%
2025-06-30	22.82%
2025-03-31	26.18%
2024-12-31	20.54%
2024-09-30	23.31%
2024-06-30	25.68%
2024-03-31	24.59%
2023-12-31	23.38%
2023-09-30	24.35%
2023-06-30	23.59%
2023-03-31	23.61%
2022-12-31	22.92%
2022-09-30	23.47%
2022-06-30	23.46%
2022-03-31	24.16%
2021-12-31	23.89%
2021-09-30	24.35%
2021-06-30	25.15%
2021-03-31	22.82%
2020-12-31	17.10%
2020-09-30	20.42%
2020-06-30	10.68%
2020-03-31	19.66%
2019-12-31	24.13%
2019-09-30	24.16%
2019-06-30	25.28%
2019-03-31	26.39%
2018-12-31	26.12%
2018-09-30	26.45%
2018-06-30	26.67%
2018-03-31	27.99%
2017-12-31	27.66%
2017-09-30	26.37%
2017-06-30	26.67%
2017-03-31	23.80%
2016-12-31	24.28%
2016-09-30	25.61%
2016-06-30	-9.36%
2016-03-31	21.84%
2015-12-31	-6.88%
2015-09-30	-8.90%
2015-06-30	18.18%
2015-03-31	7.75%
2014-12-31	11.55%
2014-09-30	9.37%
2014-06-30	2.14%
2014-03-31	17.25%
2013-12-31	12.68%
2013-09-30	11.76%
2013-06-30	17.74%
2013-03-31	-12.89%
2012-12-31	11.86%
2012-09-30	-32.05%
2012-06-30	-181.24%
2012-03-31	15.70%
2011-12-31	14.39%
2011-09-30	14.46%
2011-06-30	16.86%
2011-03-31	22.23%
2010-12-31	23.98%
2010-09-30	19.83%
2010-06-30	18.41%
2010-03-31	-69.29%
2009-12-31	-52.96%
2009-09-30	23.26%
2009-06-30	19.33%
2009-03-31	6.92%
2008-12-31	-114.09%
2008-09-30	8.04%
2008-06-30	21.64%
2008-03-31	35.34%
2007-12-31	-11.89%
2007-09-30	0.39%
2007-06-30	21.15%
2007-03-31	20.95%
2006-12-31	22.18%
2006-09-30	17.18%
2006-06-30	-178.20%
2006-03-31	33.02%
2005-12-31	32.66%
2005-09-30	-19.13%
2005-06-30	22.39%
2005-03-31	33.68%
2004-12-31	33.38%
2004-09-30	26.45%
2004-06-30	32.47%
2004-03-31	26.43%
2003-12-31	23.75%
2003-09-30	22.15%
2003-06-30	22.72%
2003-03-31	21.69%
2002-12-31	21.62%
2002-09-30	36.70%

DATE

EBITDA MARGIN

2026-06-30

25.93%

2026-03-31

27.35%

2025-12-31

29.72%

2025-09-30

27.48%

2025-06-30

22.82%

2025-03-31

26.18%

2024-12-31

20.54%

2024-09-30

23.31%

2024-06-30

25.68%

2024-03-31

24.59%

2023-12-31

23.38%

2023-09-30

24.35%

2023-06-30

23.59%

2023-03-31

23.61%

2022-12-31

22.92%

2022-09-30

23.47%

2022-06-30

23.46%

2022-03-31

24.16%

2021-12-31

23.89%

2021-09-30

24.35%

2021-06-30

25.15%

2021-03-31

22.82%

2020-12-31

17.10%

2020-09-30

20.42%

2020-06-30

10.68%

2020-03-31

19.66%

2019-12-31

24.13%

2019-09-30

24.16%

2019-06-30

25.28%

2019-03-31

26.39%

2018-12-31

26.12%

2018-09-30

26.45%

2018-06-30

26.67%

2018-03-31

27.99%

2017-12-31

27.66%

2017-09-30

26.37%

2017-06-30

26.67%

2017-03-31

23.80%

2016-12-31

24.28%

2016-09-30

25.61%

2016-06-30

-9.36%

2016-03-31

21.84%

2015-12-31

-6.88%

2015-09-30

-8.90%

2015-06-30

18.18%

2015-03-31

7.75%

2014-12-31

11.55%

2014-09-30

9.37%

2014-06-30

2.14%

2014-03-31

17.25%

2013-12-31

12.68%

2013-09-30

11.76%

2013-06-30

17.74%

2013-03-31

-12.89%

2012-12-31

11.86%

2012-09-30

-32.05%

2012-06-30

-181.24%

2012-03-31

15.70%

2011-12-31

14.39%

2011-09-30

14.46%

2011-06-30

16.86%

2011-03-31

22.23%

2010-12-31

23.98%

2010-09-30

19.83%

2010-06-30

18.41%

2010-03-31

-69.29%

2009-12-31

-52.96%

2009-09-30

23.26%

2009-06-30

19.33%

2009-03-31

6.92%

2008-12-31

-114.09%

2008-09-30

8.04%

2008-06-30

21.64%

2008-03-31

35.34%

2007-12-31

-11.89%

2007-09-30

0.39%

2007-06-30

21.15%

2007-03-31

20.95%

2006-12-31

22.18%

2006-09-30

17.18%

2006-06-30

-178.20%

2006-03-31

33.02%

2005-12-31

32.66%

2005-09-30

-19.13%

2005-06-30

22.39%

2005-03-31

33.68%

2004-12-31

33.38%

2004-09-30

26.45%

2004-06-30

32.47%

2004-03-31

26.43%

2003-12-31

23.75%

2003-09-30

22.15%

2003-06-30

22.72%

2003-03-31

21.69%

2002-12-31

21.62%

2002-09-30

36.70%

EBITDA Margin: 26.60%

BSX EBITDA Margin

BSX Average EBITDA Margin Chart

BSX Current vs Average EBITDA Margin Chart

BSX EBITDA Margin Metrics

BSX Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

BSX EBITDA Margin History

Related Metrics